ArticleCureus2025
Serum Albumin as a Prognostic Marker in Geriatric Intermediate Care: A Retrospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the prognostic value of admission serum albumin levels on six-month mortality and readmission in older adults admitted to an intermediate care facility. We hypothesized that lower albumin would be independently associated with adverse outcomes.
methodsWe conducted a retrospective cohort study at Saint Vincent de Paul Residence, including 145 intermediate care inpatients and 134 community-dwelling outpatient controls between April 2024 and March 2025. Data included demographics, frailty scores, comorbidities, CRP and albumin. Logistic regression assessed the relationship between albumin and outcomes, adjusting for age, sex, CRP, frailty and multimorbidity.
resultsMean admission albumin was 29.8 g/L in inpatients versus 40.0 g/L in controls (p<0.0001). Six-month readmission and mortality rates were 34.5% and 36.6%, respectively. Albumin independently predicted adverse composite outcomes (OR 0.439 per 5 g/L increase, p 0.003).
conclusionLow serum albumin is an independent predictor of six-month mortality and adverse outcomes in frail older adults admitted to intermediate care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.